BioNexus Gene Lab Corp
corporate_fare Company Profile
BioNexus Gene Lab Corp (NASDAQ:BGLC) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 8 items for BGLC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-14, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for BGLC spans SCHEDULE 13D, 10-Q, 10-K, 8-K.
Recent high-impact activity:
- CEO Su-Leng Tan Lee Receives 338,709 Fully Vested Shares, Boosting Stake to 11.5%
- BioNexus Issues $800K in Stock Awards, Reappoints CEO, and Reiterates Going Concern Doubt
- BioNexus Gene Lab Corp's Q1 Revenue Crashes 99% to $22.84K, Deepening Going Concern Worries
- BioNexus Gene Lab Reports 98.9% Revenue Collapse, Ongoing Going Concern Doubt, and Sues Former Officers for $2.9M
- Annual Report Reveals Going Concern Doubt, Material Weakness, and Significant Dilution Risks
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for BGLC, detected from its recent SEC filings · based on capital-structure filings through 2026-04-14.
Going Concern Warning Issued · Material Weakness in Internal Controls
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →